Biopharma · FDA Approvals · Stock

CNTB Connect Biopharma

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical …

Assets on file: rademikibart

Start live analysis of CNTB Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for CNTB, including recently decided ones.

December 2026

Dec 2026

~ Dec 2026

CNTBConnect Biopharma

rademikibart: Phase 2 trial NCT07705737 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for CNTB, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 22, 2026

03:23 PM

CNTBConnect Biopharma

rademikibart · NCT07705737 registry update

countries: {'total_sites': 2, 'us_sites': 2} → {'total_sites': 3, 'us_sites': 3}

Trial registry changeClinicalTrials.gov

Sep 16, 2026

03:22 PM

CNTBConnect Biopharma

rademikibart · NCT06940141 registry update

status: ACTIVE_NOT_RECRUITING → COMPLETED

Trial registry changeClinicalTrials.gov Open record1 update

Mar 30, 2026

11:06 AM

CNTBConnect Biopharma

Connect Biopharma reports Phase 3 topline results for rademikibart in atopic dermatitis

The 8-K discloses topline results from a Phase 3 52-week study of rademikibart in moderate-to-severe atopic dermatitis conducted by partner Simcere in China. A separate Phase 1 IV pharmacology study topline was also released. These data releases constitute the regulatory/clinical milestone event.

Topline resultsSEC 8-K Open record4 updates

Nov 12, 2025

02:02 PM

CNTBConnect Biopharma

CNTB: Simcere NDA for rademikibart in AD accepted by China NMPA

Simcere, Connect’s exclusive Greater China licensee, submitted and received NMPA acceptance of its NDA for rademikibart in adult and adolescent atopic dermatitis. The acceptance triggers eligibility for up to ~$110 million in remaining development, regulatory and commercial milestones plus tiered low double-digit royalties on Greater China sales. No U.S. regulatory action is reported.

Application acceptedSEC 8-K Open record